Summary
Data from a Phase 2b study suggest that baricitinib, an oral JAK1/JAK2 inhibitor, is an efficacious treatment for rheumatoid arthritis when used in combination with traditional disease-modifying antirheumatic drugs.
- Rheumatoid Arthritis Clinical Trials
- © 2012 MD Conference Express®